BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
BioLineRx Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026
$1.98−0.03 (-1.49%)
Close on Oct 19, 2026
- Market cap
- $5.28B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0.0%
0M of 2.61B shares
Institutional holders
14
4 new, 3 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Highbridge Capital Management, LLC | 172,950,600 | 7.20% | 13G (passive) | Jun 30, 2025 |
| Lepu (Hong Kong) Co., Limited | 102,437,055 | 9.50% | 13D (active) | Oct 9, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BLRX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Susquehanna International Group, Llp | 30,911 | 0.00% | $95.82K | New | 0.00% |
| Renaissance Technologies LLC | 15,412 | 0.00% | $48.09K | New | 0.00% |
| Citadel Advisors LLC | 14,796 | 0.00% | $45.87K | New | 0.00% |
| Rhumbline Advisers | 2,478 | 0.00% | $7.68K | +125 | 0.00% |
| Wells Fargo & Company/Mn | 2,000 | 0.00% | $6.24K | +250 | 0.00% |
| Bnp Paribas Arbitrage, Snc | 500 | 0.00% | $1.55K | −1,300 | 0.00% |
| Nemes Rush Group LLC | 250 | 0.00% | $780 | – | 0.00% |
| UBS Group AG | 101 | 0.00% | $315 | −428 | 0.00% |
| NewEdge Advisors, LLC | 82 | 0.00% | $256 | −25 | 0.00% |
| Osaic Holdings, Inc. | 26 | 0.00% | $81 | – | 0.00% |
| SBI Securities Co., Ltd. | 10 | 0.00% | $31 | New | 0.00% |
| Danske Bank A/S | 2 | 0.00% | $6 | – | 0.00% |
| Citigroup Inc | 1 | 0.00% | $3 | −1,727 | 0.00% |
| Banque Cantonale Vaudoise | 1 | 0.00% | $1.00K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 14 | 0M | 0.0% | 4 / 2 | 4 / 3 | 0M | 0M |
| Q1 2026 | 13 | 0M | 0.0% | 1 / 1 | 3 / 2 | 0M | 0M |
| Q4 2025 | 14 | 0M | 0.0% | 3 / 4 | 2 / 3 | 0M | 0M |
| Q3 2025 | 14 | 0M | 0.0% | 3 / 1 | 3 / 6 | 0M | 0M |
| Q2 2025 | 17 | 0M | 0.0% | 9 / 1 | 3 / 4 | 0M | 0M |
| Q1 2025 | 12 | 0M | 0.0% | 12 / 0 | 0 / 1 | 0M | 0M |
| Q4 2024 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Philip A. Serlin | Chief Executive Officer | 5,131,800 | 0.20% | Mar 27, 2026 |
| Mali Zeevi | Chief Financial Officer | 1,311,000 | 0.05% | Mar 18, 2026 |
| Shaoyu Yan | Director | – | – | Apr 10, 2026 |
| Sandra Panem | Director | – | – | Mar 31, 2026 |
| Rami Dar | Director | – | – | Mar 31, 2026 |
| Avraham Molcho | Director | – | – | Mar 31, 2026 |
| Raphael Hofstein | Director | – | – | Mar 31, 2026 |
| Gal Avraham Cohen | Director | – | – | Mar 30, 2026 |
| Aharon Schwartz | Director | 3,705,000 | 0.14% | Mar 30, 2026 |
| Barbara-Jean Anne Bormann-Kennedy | Director | – | – | Mar 18, 2026 |